Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
2190-9172
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis ; volume:12 ; number:6 ; day:27 ; month:4 ; year:2022 ; pages:1303-1311 ; date:6.2022
Dermatology and therapy ; 12, Heft 6 (27.4.2022), 1303-1311, 6.2022

Urheber
Bellinato, Francesco
Gisondi, Paolo
Mason, Elena
Ricci, Paolo
Maurelli, Martina
Girolomoni, Giampiero
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s13555-022-00732-y
URN
urn:nbn:de:101:1-2022081319022195325312
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:30 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Bellinato, Francesco
  • Gisondi, Paolo
  • Mason, Elena
  • Ricci, Paolo
  • Maurelli, Martina
  • Girolomoni, Giampiero
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Humira (Adalimumab) : Adalimumab in der Therapie der Psoriasis

Fallstudiensammlung

Humira (Adalimumab) : Adalimumab in der Therapie der Psoriasis

Biosimilars – Biosimilars: ja, aber

Biosimilars – Biosimilars: ja, aber

Plaque-Psoriasis – Ponesimod zeigt Wirksamkeit

Plaque-Psoriasis – Ponesimod zeigt Wirksamkeit

Minimale Krankheitsaktivität nach Adalimumab-Therapie bei Psoriasis-Arthritis

Minimale Krankheitsaktivität nach Adalimumab-Therapie bei Psoriasis-Arthritis

Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents

Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents

Ustekinumab : Behandlung der Plaque-Psoriasis und aktiven Psoriasis-Arthritis

Ustekinumab : Behandlung der Plaque-Psoriasis und aktiven Psoriasis-Arthritis

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis

Biosimilars

Biosimilars

Orale Psoriasis-Therapie mit Deucravacitinib : mittelschwere bis schwere Plaque-Psoriasis

Orale Psoriasis-Therapie mit Deucravacitinib : mittelschwere bis schwere Plaque-Psoriasis

Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial

Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial

Correction to: Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents

Correction to: Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents

Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis

Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis

Verbundene Objekte